GSK ends dementia alliance with Alector after setbacks

Pharmaphorum

GSK's alliance with Alector to develop two drug candidates for dementia has been terminated in the wake of disappointing clinical trial results.

pharminent July 9, 2026 (Last updated: July 10, 2026)

Pharmaphorum

GSK’s alliance with Alector to develop two drug candidates for dementia has been terminated in the wake of disappointing clinical trial results.

Related Stories